Status:
COMPLETED
Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
Tumor, Solid
Positron-Emission Tomography
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To evaluate the potential usefulness of 68Ga-FAP-2286 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and comp...
Detailed Description
Subjects with various types of cancer underwent contemporaneous 68Ga-FAP-2286 and 18F-FDG PET/CT either for an initial assessment or for recurrence detection. Tumor uptake was quantified by the maximu...
Eligibility Criteria
Inclusion
- adult patients (aged 18 years or order);
- patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);
- patients who had scheduled both 18F-FDG and 68Ga-FAP-2286 PET/CT scans;
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion
- patients with non-malignant lesions;
- patients with pregnancy;
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent;
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT05392205
Start Date
March 1 2022
End Date
October 31 2022
Last Update
February 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First affiliated hospital of xiamen university
Xiamen, Fujian, China, 361000